Arvinas, Inc
ARVNArvinas, Inc. is a biotechnology company specializing in the development of targeted protein degradation therapies. Founded to leverage innovative PROTAC (Proteolysis Targeting Chimera) technology, Arvinas focuses on creating treatments for various diseases, including cancer and neurodegenerative disorders. The company aims to address unmet medical needs by selectively degrading disease-causing proteins, offering potential for more effective and precise therapeutics.
Company News
Researchers at University of Technology Sydney have developed nanoparticle-mediated targeting chimeras (NPTACs), a new technology that can degrade disease-causing proteins to treat conditions like dementia, brain cancer, and autoimmune disorders. The technology overcomes limitations of conventional targeted protein degradation tools and has shown...
Arvinas presented preclinical data showing enhanced antitumor activity when combining ARV-393 and glofitamab in a high-grade B-cell lymphoma model, with plans to initiate a Phase 1 clinical trial combination cohort in 2026.
Arvinas will present multiple research abstracts about vepdegestrant, an investigational drug for estrogen receptor positive breast cancer, at the San Antonio Breast Cancer Symposium in December 2025. The drug is being co-developed with Pfizer and is currently under FDA review.
Arvinas will present preclinical data for ARV-393, a PROTAC BCL6 degrader targeting non-Hodgkin lymphoma, at the 2025 ASH Annual Meeting in Orlando, Florida.
Arvinas presented promising preclinical data for ARV-806, a targeted protein degradation drug designed to address KRAS G12D mutations in cancers like pancreatic, colorectal, and lung cancer, demonstrating robust protein degradation and potential therapeutic benefits.
